| US 7,488,719 B1 | ||
| Wound and cutaneous injury healing with a nucleic acid encoding perlecan | ||
| Arthur A. DeCarlo, Weston, Fla. (US); and John Whitelock, Sydney (Australia) | ||
| Assigned to Agenta Biotechnologies, Inc., Birmingham, Ala. (US) | ||
| Filed on Nov. 27, 2006, as Appl. No. 11/604,633. | ||
| Application 11/604633 is a continuation of application No. 10/420270, filed on Apr. 22, 2003, granted, now 7,141,551, filed on Nov. 28, 2006. | ||
| Claims priority of provisional application 60/374553, filed on Apr. 22, 2002. | ||
| This patent is subject to a terminal disclaimer. | ||
| Int. Cl. A01K 63/00 (2006.01); A61K 48/00 (2006.01) | ||
| U.S. Cl. 514—44 [424/93.2; 424/93.21] | 15 Claims |
| 1. A method for the effective healing of a wound or a cutaneous injury in a subject in need of such healing via delivery of a heparin sulfate-decorated perlecan molecule, the method comprising administering to the wound or cutaneous injury in the subject a nucleic acid coding for perlecan whereby said heparin sulfate-decorated perlecan molecule is generated by the subject, said nucleic acid being delivered in an amount sufficient to deliver an effective amount of heparin sulfate-decorated perlecan to the wound or cutaneous injury resulting in an in improvement in healing of the wound or cutaneous injury in the subject. |